Free Newsletter
SPOTLIGHT: Brain cancer vaccine doubles survival time
An experimental brain cancer vaccine more than doubled the survival time of patients suffering from glioblastoma multiforme. Early-stage data demonstrated that patients lived almost three years after taking the vaccine for a disease that typically kills people after one year. Report
More stories about glioblastoma
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
